SCHEMBL4407549

SCHEMBL4407549

CSc1nccc(-c2cc3c(C)noc3nc2-c2ccc(F)cc2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.48
CSNK1D P48730 2/20 0.48
JAK3 P52333 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
POLB P06746 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CCNA2 P20248 2/20 0.45
CDK2 P24941 2/20 0.45
CDK5 Q00535 2/20 0.45
CDK5R1 Q15078 2/20 0.45
CSNK1E P49674 1/20 0.45
MAPK13 O15264 4/20 0.41
MAPK12 P53778 4/20 0.41
MAPK11 Q15759 4/20 0.41
LMNA P02545 3/20 0.39
ALDH1A1 P00352 3/20 0.37
GAA P10253 2/20 0.36
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4409899 0.81 ALDH1A1 (0.40) MAPK14MAPK13MAPK12MAPK11LMNA
SCHEMBL4409134 0.81 MAPK14 (0.47) MAPK14CSNK1DJAK3L3MBTL1POLB
SCHEMBL1385209 0.81 MAPK14 (0.49) MAPK14CSNK1DJAK3L3MBTL1POLB
SCHEMBL4408264 0.78 DYRK1A (0.40) MAPK14MAPK13MAPK12MAPK11LMNA
SCHEMBL1385351 0.76 CDK2 (0.51) MAPK14CSNK1DJAK3L3MBTL1POLB
SCHEMBL4408259 0.76 MAP4K4 (0.50) MAPK14CSNK1DCDK2MAPK13MAPK12
SCHEMBL2926468 0.75 MAPK14 (0.48) MAPK14CSNK1DJAK3L3MBTL1POLB
SCHEMBL4408485 0.75 MAPK13 (0.55) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL4408488 0.75 MAPK13 (0.55) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL4411071 0.75 CSNK1E (0.52) MAPK14CSNK1DJAK3L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US disclosed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US disclosed
EP-1833828-A2 CONDENSED PYRIDINES AS KINASE INHIBITORS Palau Pharma, S.A. (ES) 2007-09-19 EP disclosed
WO-2006013095-A2 CONDENSED PYRIDINES AS KINASE INHIBITORS PALAU PHARMA, S.A. (ES) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 MAPK14 36/4885CSNK1D 172/4885JAK3 515/4885
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 MAPK14 36/4885CSNK1D 172/4885JAK3 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.